


This panel aids in prognostication and therapeutic decisions for Lung carcinoma where mutation has been demonstrated in ALK, BRAF, EGFR, ERBB2, KRAS, MAP2K1, MET, NRAS, PIK3CA, ROS1, TP53 and Fusion in ALK, RET, ROS1, NTRK; MET exon 14 skipping. It also enables the screening of clinically actionable targets for personalized targeted medicine in Lung adenocarcinoma. PD-L1 (SP263) expression by IHC is used to guide immunotherapy decisions.